AU2015417382A1 - Crystalline forms of quinolone analogs and their salts - Google Patents

Crystalline forms of quinolone analogs and their salts Download PDF

Info

Publication number
AU2015417382A1
AU2015417382A1 AU2015417382A AU2015417382A AU2015417382A1 AU 2015417382 A1 AU2015417382 A1 AU 2015417382A1 AU 2015417382 A AU2015417382 A AU 2015417382A AU 2015417382 A AU2015417382 A AU 2015417382A AU 2015417382 A1 AU2015417382 A1 AU 2015417382A1
Authority
AU
Australia
Prior art keywords
crystalline form
pct
cancer
compound
exhibits
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2015417382A
Other languages
English (en)
Inventor
Hshiou-Ting Liu
David M. Ryckman
Iching Grace Yu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Senhwa Biosciences Inc
Original Assignee
Senhwa Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Senhwa Biosciences Inc filed Critical Senhwa Biosciences Inc
Publication of AU2015417382A1 publication Critical patent/AU2015417382A1/en
Priority to AU2021203085A priority Critical patent/AU2021203085B2/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AU2015417382A 2015-12-14 2015-12-14 Crystalline forms of quinolone analogs and their salts Abandoned AU2015417382A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2021203085A AU2021203085B2 (en) 2015-12-14 2021-05-14 Crystalline forms of quinolone analogs and their salts

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2015/065443 WO2017105382A1 (en) 2015-12-14 2015-12-14 Crystalline forms of quinolone analogs and their salts

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2021203085A Division AU2021203085B2 (en) 2015-12-14 2021-05-14 Crystalline forms of quinolone analogs and their salts

Publications (1)

Publication Number Publication Date
AU2015417382A1 true AU2015417382A1 (en) 2018-06-14

Family

ID=59057173

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2015417382A Abandoned AU2015417382A1 (en) 2015-12-14 2015-12-14 Crystalline forms of quinolone analogs and their salts
AU2021203085A Active AU2021203085B2 (en) 2015-12-14 2021-05-14 Crystalline forms of quinolone analogs and their salts

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2021203085A Active AU2021203085B2 (en) 2015-12-14 2021-05-14 Crystalline forms of quinolone analogs and their salts

Country Status (10)

Country Link
EP (2) EP4249072A3 (https=)
JP (1) JP2018537486A (https=)
KR (1) KR20180111797A (https=)
CN (1) CN108699083A (https=)
AU (2) AU2015417382A1 (https=)
CA (2) CA3006502A1 (https=)
ES (1) ES2959536T3 (https=)
IL (1) IL260004A (https=)
RU (1) RU2018124599A (https=)
WO (1) WO2017105382A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112334133A (zh) * 2018-02-15 2021-02-05 生华生物科技股份有限公司 喹诺酮类似物及其盐、组合物及其使用方法
CA3129722A1 (en) * 2019-02-11 2020-08-20 Phoenix Molecular Designs Crystalline forms of an rsk inhibitor
CA3151116A1 (en) * 2019-08-14 2021-02-18 Hshiou-Ting Liu Crystalline forms of quinoline analogs and salts thereof, compositions, and their methods for use
EP4013421A4 (en) * 2019-08-14 2023-08-23 Senhwa Biosciences, Inc. TETRACYCLIC COMPOUNDS AND THEIR SALTS, COMPOSITIONS AND METHODS OF USE
JP2020189888A (ja) * 2020-08-28 2020-11-26 センワ バイオサイエンシズ インコーポレイテッド キノロン類似体及びその塩の結晶形
CN118005653B (zh) * 2023-04-23 2024-12-10 信义核新(北京)生物科技有限公司 喹诺酮类似物及其用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006034113A2 (en) * 2004-09-17 2006-03-30 Cylene Pharmaceuticals, Inc. Quinolone analogs as cell proliferation inhibitors
JP2009504192A (ja) * 2005-08-19 2009-02-05 サイリーン ファーマシューティカルズ インコーポレーティッド ヒトリボソームＤＮＡ（ｒＤＮＡ）およびリボソームＲＮＡ（ｒＲＮＡ）核酸ならびにそれらの使用
US7928100B2 (en) 2007-10-05 2011-04-19 Cylene Pharmaceuticals, Inc. Quinolone analogs and methods related thereto
US20140086839A1 (en) * 2011-03-17 2014-03-27 Tel Hashomer Medical Research Infrastructure And Services Ltd. Quinolone analogs for treating autoimmune diseases
ES2754207T3 (es) * 2013-11-28 2020-04-16 Tel Hashomer Medical Res Infrastructure & Services Ltd Inhibidores de la ARN polimerasa I y usos de los mismos

Also Published As

Publication number Publication date
JP2018537486A (ja) 2018-12-20
EP3394070A1 (en) 2018-10-31
CN108699083A (zh) 2018-10-23
AU2021203085A1 (en) 2021-06-10
EP3394070B1 (en) 2023-08-02
EP4249072A2 (en) 2023-09-27
IL260004A (en) 2018-07-31
EP3394070A4 (en) 2019-05-08
ES2959536T3 (es) 2024-02-26
AU2021203085B2 (en) 2023-06-08
EP4249072A3 (en) 2023-10-25
CA3255938A1 (en) 2025-11-28
RU2018124599A (ru) 2020-01-16
KR20180111797A (ko) 2018-10-11
CA3006502A1 (en) 2017-06-22
EP3394070C0 (en) 2023-08-02
WO2017105382A1 (en) 2017-06-22
RU2018124599A3 (https=) 2020-01-16

Similar Documents

Publication Publication Date Title
AU2021203085B2 (en) Crystalline forms of quinolone analogs and their salts
US9957282B2 (en) Crystalline forms of quinolone analogs and their salts
JP6657294B2 (ja) ニューロトロフィン模倣化合物およびこれらの塩の結晶形態
US20220162177A1 (en) Crystalline forms of neurotrophin mimetic compounds and their salts
KR20200081359A (ko) 2-(5-(4-(2-모르폴리노에톡시)페닐)피리딘-2-일)-n-벤질아세트아미드의 고체 형태
JP2015535842A (ja) ニューロトロフィン模倣化合物の結晶形及びその塩
JP2022179783A (ja) キノロン類似体及びその塩の結晶形
US20210046082A1 (en) Crystalline forms of quinoline analogs and salts thereof, compositions, and their methods for use
HK40098923A (en) Crystalline forms of quinolone analogs and their salts
HK1262794A1 (en) Crystalline forms of quinolone analogs and their salts
HK1262794B (en) Crystalline forms of quinolone analogs and their salts
TWI765848B (zh) 喹諾酮類似物及其鹽的結晶形式

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted